[go: up one dir, main page]

Zampar et al., 2024 - Google Patents

“Prion-like” seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders

Zampar et al., 2024

View HTML
Document ID
666371998381990101
Author
Zampar S
Di Gregorio S
Grimmer G
Watts J
Ingelsson M
Publication year
Publication venue
Frontiers in neuroscience

External Links

Snippet

Intra-or extracellular aggregates of proteins are central pathogenic features in most neurodegenerative disorders. The accumulation of such proteins in diseased brains is believed to be the end-stage of a stepwise aggregation of misfolded monomers to insoluble …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Similar Documents

Publication Publication Date Title
Scialò et al. Prion and prion-like protein strains: deciphering the molecular basis of heterogeneity in neurodegeneration
Vasili et al. Spreading of α-synuclein and tau: a systematic comparison of the mechanisms involved
Stroo et al. Cellular regulation of amyloid formation in aging and disease
Ma et al. Prion-like mechanisms in Parkinson’s disease
Ugalde et al. Pathogenic mechanisms of prion protein, amyloid‐β and α‐synuclein misfolding: The prion concept and neurotoxicity of protein oligomers
Haass et al. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Bagheri et al. Role of copper in the onset of Alzheimer’s disease compared to other metals
Nonaka et al. Seeded aggregation and toxicity of α-synuclein and tau: cellular models of neurodegenerative diseases
Herms et al. Dendritic spine pathology in neurodegenerative diseases
Lasagna-Reeves et al. Preparation and characterization of neurotoxic tau oligomers
Goedert Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein
Peelaerts et al. ɑ‐Synuclein strains and the variable pathologies of synucleinopathies
Zampar et al. “Prion-like” seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders
Caughey et al. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders
LaFerla et al. Intracellular amyloid-β in Alzheimer's disease
Guo et al. Distinct α-synuclein strains differentially promote tau inclusions in neurons
Ono et al. Low‐n oligomers as therapeutic targets of Alzheimer’s disease
Zhu et al. Pharmacological inhibition of O-GlcNAcase enhances autophagy in brain through an mTOR-independent pathway
de Rus Jacquet et al. Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders
Vadukul et al. α-Synuclein aggregation is triggered by oligomeric amyloid-β 42 via heterogeneous primary nucleation
Clavaguera et al. Prion-like properties of Tau assemblies
Perez et al. Mechanism of fibril and soluble oligomer formation in amyloid beta and hen egg white lysozyme proteins
Angelova et al. Altered processing of β-amyloid in SH-SY5Y cells induced by model senescent microglia
Fessel Amyloid is essential but insufficient for Alzheimer causation: addition of subcellular cofactors is required for dementia
Wildburger et al. Current evidence for a bidirectional loop between the lysosome and alpha-synuclein proteoforms